-transparent.png){kind=logo}
MS-209, a novel quinoline derivative, was examined for its reversing effect on multidrug-resistant tumor cells. MS-209 at 1-10 microM completely reversed resistance against vincristine (VCR) in vitro in multidrug-resistant variants of mouse leukemia P388 cells (VCR-resistant P388/VCR and Adriamycin (ADM)-resistant P388/ADM) and human leukemia K562 cells (VCR-resistant K562/VCR and ADM-resistant K562/ADM). MS-209 at 1-10 microM also completely reversed resistance against ADM in vitro in P388/VCR cells, K562/VCR cells, and K562/ADM cells. In ADM-resistant P388 (P388/ADM) cells, however, ADM resistance was only partially reversed at the MS-209 concentrations tested. MS-209 enhanced the chemotherapeutic effect of VCR in P388/VCR-bearing mice. When MS-209 was given p.o. at 80 mg/kg twice a day (total dose, 160 mg/kg per day) with 100 micrograms/kg VCR, a treated/control (T/C) value of 155% was obtained. MS-209 also enhanced the chemotherapeutic effect of ADM in P388/ADM-bearing mice. The most prominent effects were obtained when MS-209 was given with 2 mg/kg ADM, yielding T/C values of 150%-194% for the combined treatment at an MS-209 dose of 200-450 mg/kg. MS-209 inhibited [3H]-azidopine photolabeling of P-glycoprotein efficiently. Furthermore, the accumulation of ADM in K562/ADM cells was increased more efficiently by MS-209 than by verapamil. These results indicate that MS-209, like verapamil, directly interacts with P-glycoprotein and inhibits the active efflux of antitumor agents, thus overcoming multidrug resistance in vitro and in vivo.
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
May 1997,
Nihon rinsho. Japanese journal of clinical medicine,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
January 1997,
Cancer chemotherapy and pharmacology,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
February 1999,
Biochemical and biophysical research communications,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
January 1998,
Anticancer research,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
July 2001,
Japanese journal of cancer research : Gann,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
January 1998,
Cancer chemotherapy and pharmacology,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
February 2002,
Clinical cancer research : an official journal of the American Association for Cancer Research,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
October 1998,
British journal of cancer,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
January 2015,
Journal of Asian natural products research,
W Sato, and
N Fukazawa, and
O Nakanishi, and
M Baba, and
T Suzuki, and
O Yano, and
M Naito, and
T Tsuruo
March 1999,
Bioorganic & medicinal chemistry letters,
